News Search Results
Nov 19, 2025, 07:30 ET Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
enroller in the Phase 3 FLASH study. About Cutaneous T-Cell Lymphoma (CTCL) CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike
More news about: SOLIGENIX, INC.
Nov 18, 2025, 16:15 ET Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Nov 18, 2025, 12:47 ET AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
treatment.i "Recurrent follicular lymphoma can be an incurable, complex and persistent disease, creating a clear need for additional treatments that can change its course earlier in the treatment journey," said Lorenzo Falchi, M.D., lymphoma specialist, department of medicine, Memorial Sloan
More news about: AbbVie
Nov 14, 2025, 12:30 ET AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
today the launch of Second Winds, a new short film that captures the powerful, deeply personal journeys of three people living with chronic lymphoma leukemia (CLL), a common type of blood cancer effecting hundreds of thousands of people in the United States.1,2 Each person's dynamic
More news about: AbbVie
Nov 14, 2025, 09:26 ET Curis to Present at Upcoming 30th Annual SNO Meeting
available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society
More news about: Curis, Inc.
Nov 12, 2025, 09:30 ET Pillar Biosciences Enables Rapid, Localized Tumor Profiling of Lymphoid Malignancies with Launch of New Kitted NGS Panel
States is diagnosed with leukemia, lymphoma, or myeloma. An estimated combined total of 187,740 people in the U.S. were expected to be diagnosed with leukemia, lymphoma or myeloma in 2024. New cases of leukemia, lymphoma, and myeloma were expected to account
More news about: Pillar Biosciences, Inc.
Nov 11, 2025, 02:34 ET Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
cancer, Fosun Kairos' CAR-T cell therapy product Yi Kai Da (ejilunsai injection), the first CAR-T therapy approved in China, continues to advance lymphoma treatment by making it both accessible and potentially curative. Following Yi Kai Da, Fosun Kairos' second CAR-T product, brexucabtagene autoleucel
More news about: Fosun
Nov 10, 2025, 09:48 ET Bracco Shapes the Future of Radiology at RSNA 2025 Annual Meeting
Images (for performance testing) spanning a variety of pathologies including patients with Cerebritis, Glioma, Inflammation, Lymphoma, Meningioma, Metastatic lesions, Multiple sclerosis, Neuritis, other tumor-related lesions (e.g., resection/radiation necrosis / suspected cyst / etc.),
More news about: Bracco Group
Nov 10, 2025, 07:30 ET ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
investigator-initiated trial (IIT) of ZYNLONTA in r/r follicular lymphoma (FL) presented at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL). Juan Pablo Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the
More news about: ADC Therapeutics SA
Nov 07, 2025, 09:00 ET HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
dose-proportional pharmacokinetics. Confirmed partial responses seen in head and neck squamous cell carcinoma (HNSCC) and marginal zone lymphoma (MZL). Several patients achieved stable disease, with progression-free survival up to 32 weeks.
More news about: HanchorBio Inc.
Nov 07, 2025, 07:30 ET Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
hypericin) and an enrollment update for the confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL)," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "Recently, we were pleased to announce that the first
More news about: SOLIGENIX, INC.
Nov 06, 2025, 16:00 ET Curis Provides Third Quarter 2025 Business Update
NHL/CLL Curis will report clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23:
More news about: Curis, Inc.
Nov 06, 2025, 10:00 ET Healthcare-Focused Secondaries Manager Revelation Partners Expands Investment Team, Promotes Eric Shiozaki to Partner
Having initially trained as a structural biologist, he has been published in leading scientific journals and served as a Leukemia & Lymphoma Society Post-Doctoral Fellow. Shiozaki received a bachelor of arts degree in biophysics from Johns Hopkins University and a Ph.D. in molecular biology
More news about: Revelation Partners
Nov 06, 2025, 01:27 ET Fosun Marks Eighth Year at CIIE, Guo Guangchang Calls for More Cutting-Edge Innovation
oncology, Fosun's Yi Kai Da (ejilunsai injection), China's first CAR-T cell therapy product, continues to share the latest developments in making lymphoma treatment both accessible and curative at the CIIE. This year, Yi Kai Da has made multiple major advances: inclusion in over 110 urban customized
More news about: Fosun
Nov 05, 2025, 07:00 ET HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
pharmacodynamics (PD), and preliminary clinical efficacy of HCB301 in patients with advanced solid tumors or relapsed and refractory classical Hodgkin lymphoma. About HanchorBioBased in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx:
More news about: HanchorBio Inc.
Nov 04, 2025, 16:25 ET Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology
and functional restoration of intestinal integrity. By selectively degrading MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), TE205 effectively: Suppressed NF-κB signaling and
More news about: Eilean Therapeutics
Nov 04, 2025, 16:05 ET Cryoport Reports Third Quarter 2025 Financial Results
another supplemental approval from the EC to expand the label of Breyanzi® as a third line treatment for relapsed or refractory follicular lymphoma. During the remainder of 2025, we anticipate up to an additional 7 application filings, 1 new therapy approval and an additional 2 approvals for label/geographic
More news about: Cryoport, Inc.
Nov 03, 2025, 22:23 ET 【2025 ASH】 亞盛醫藥Bcl-2抑制劑利沙托克拉兩項臨床研究入選，含1項口頭報告！
registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)
More news about: 亞盛醫藥
Nov 03, 2025, 20:22 ET 【2025 ASH】亞盛醫藥耐立克®多項研究入選，POLARIS-1研究數據首次發布
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)
More news about: 亞盛醫藥
Nov 03, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Nov 03, 2025, 16:05 ET AAVivo, Inc. to Present at Society for Immunotherapy of Cancer 2025
CD19-specific T cells from non-activated T cells in human PBMCs both in vitro and in vivo and the CAR-T cells can control the growth of Raji lymphoma in vitro and in NSG mice. "We are pleased that a poster highlighting the potential of our iAAV platform to rapidly enable in
More news about: AAVivo, Inc.
Nov 03, 2025, 13:31 ET Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting
Poster presentations at ASH highlight advances in the understanding and research of Castleman disease, cold agglutinin disease, B-cell lymphoma, and other hematologic conditions BRIDGEWATER, N.J.,
More news about: Recordati
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
reported clinical trials (NCT07053670, NCT06734871) had enrolled 14 patients, including 3 with follicular lymphoma (FL), 3 with mantle cell lymphoma (MCL), and 8 with diffuse large B-cell lymphoma (DLBCL). The dose escalation study has been completed, preliminarily determining the recommended lymphodepletion
More news about: CARsgen Therapeutics
Nov 03, 2025, 07:15 ET ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In
More news about: ADC Therapeutics SA
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.